Alzamend Neuro has regained compliance with Nasdaq Listing Rule 5550(b)(1), after reporting stockholders’ equity of $5,802,680 for the quarter ended July 31, 2026, above the $2.5 million minimum. Nasdaq’s Listing Qualifications Staff notified the company on September 14 that the matter was closed. Alzamend had submitted a compliance plan after a March 20 notice and received until September 16 to regain compliance. The company said it will now focus on advancing AL001 through four Phase II clinical trials with Massachusetts General Hospital. The healthy human cohort completed its clinical portion in November 2025, topline data were reported in March 2026, and the bipolar disorder cohort began in April 2026. Alzamend also develops ALZN002, a cell-based therapeutic vaccine for Alzheimer’s disease.